logoTry Persana

Atomwise - Company Overview, Founder, CEO, Funding & Investment Details

Complete information about Atomwise including founder details, CEO information, total funding raised, headquarters location, team size, and recent investment rounds.

Atomwise company logo

Better Medicines Faster

Atomwise is a preclinical pharma company revolutionizing drug discovery with AI technology. The company focuses on developing its own pipeline while nurturing numerous collaborations with researchers and pharmaceutical firms worldwide.

HeadquartersSan Francisco, California, United States
Team size31-50
Founded2012

What is Atomwise? - Company Overview & Details

Atomwise is Atomwise is a preclinical pharma company revolutionizing drug discovery with AI technology. The company focuses on developing its own pipeline while nurturing numerous collaborations with researchers and pharmaceutical firms worldwide. Founded in 2012, the company is headquartered in San Francisco, California, United States.

Who Founded Atomwise?

Atomwise was founded by Abraham Heifets, Izhar Wallach.

Who are the Key Executives at Atomwise? - Leadership Team

Atomwise is led by experienced executives in key positions:

Chief Executive Officer (CEO) of Atomwise

Steve WorlandCEO

Chief Technology Officer (CTO) of Atomwise

Izhar WallachCTO

About Steve Worland - CEO of Atomwise

Steve Worland serves as the Chief Executive Officer of Atomwise, leading the company's strategic vision and operations. Connect with them on LinkedIn for professional insights.

Atomwise Company Details & Key Information

Where is Atomwise located?

Atomwise is headquartered in San Francisco, California, United States.

How many employees does Atomwise have?

Atomwise has 31-50 employees.

When was Atomwise founded?

Atomwise was founded in 2012.

Atomwise Official Website

How much funding has Atomwise raised?

Atomwise has raised $175 Million across 10 funding rounds. The most recent funding was completed on 2024-02-01.

Funding Overview

Atomwise has raised a total of $175 million across multiple funding rounds to advance its AI-driven drug discovery technology.

$175 Million
Total Funding Raised
10
Funding Rounds
2024-02-01
Latest Round

Atomwise Funding History

Series C
2024-02-01
$45 Million
Grant
2020-11-06
$2.3 Million

Who are the key investors in Atomwise?

Atomwise is backed by 3 key investors including Bill & Melinda Gates Foundation, B Capital Group, Sanabil Investments. These investors focus on Healthcare, Pharmaceuticals, Biotech sectors.

Atomwise Investor Overview

3
Key Investors
4
Focus Areas
3
Notable Investments

Complete List of Atomwise Investors

Bill & Melinda Gates Foundation

Invested in Atomwise to support AI-based drug discovery for neglected diseases.

Investment Focus
Healthcare
Pharmaceuticals
Notable Portfolio Companies
$2.3M Grant

B Capital Group

A global venture capital firm investing in technology-centric healthcare companies.

Investment Focus
Healthcare
Biotech
Notable Portfolio Companies
$123M Series B

Sanabil Investments

Investment firm backed by Saudi Arabia's sovereign wealth fund focusing on global opportunities.

Investment Focus
Venture Capital
Biotech
Notable Portfolio Companies
$123M Series B

What sectors do Atomwise investors focus on?

The investors backing Atomwise primarily focus on Healthcare, Pharmaceuticals, Biotech, Venture Capital sectors.

Healthcare
Pharmaceuticals
Biotech
Venture Capital

Featured Investor: Bill & Melinda Gates Foundation

Bill & Melinda Gates Foundation

Invested in Atomwise to support AI-based drug discovery for neglected diseases.

Notable Investments: $2.3M Grant

What are Atomwise's future plans?

Atomwise Atomwise aims to enhance its internal drug pipeline and expand collaborations with academic and industry partners.

Atomwise Strategic Outlook

Strategic Focus
Defined
2
Key Challenges
2
Growth Opportunities

What challenges does Atomwise face?

Atomwise has identified 2 key challenges that need to be addressed for continued growth and success.

Key Challenges for Atomwise

1

Competition in AI drug discovery

2

Regulatory hurdles

What opportunities does Atomwise have?

Atomwise has identified 2 key opportunities for growth and market expansion.

Growth Opportunities for Atomwise

1

Expanding partnerships

2

Innovating in drug discovery technologies

Atomwise Strategic Position Summary

Key Focus Areas

Atomwise is addressing 2 strategic challenges to strengthen its market position.

Growth Potential

The company has identified 2 key opportunities for expansion and growth.

What are the latest news about Atomwise?

Atomwise has 2 recent news updates covering key business developments and market activities.

Atomwise News Overview

2
Recent Articles
Active
Media Coverage
2025-02-19
Latest Update

What is Atomwise in the news for?

Atomwise is currently featured in news for Atomwise Inc. hired Steve Worland as Chief Executive Officer on Feb 18th '25. and other significant business developments.

Recent News Articles About Atomwise

Article 1
2025-02-19

Atomwise Inc. hired Steve Worland as Chief Executive Officer on Feb 18th '25.

Atomwise appoints Steve Worland, Ph.D. as Chief Executive Officer.

readmagazine.com
Read News
Article 2
2023-03-22

Atomwise Inc. launched A.I. based 'AtomNet PoseRanker on Feb 23rd '23.

Atomwise recently introduced A.I. based 'AtomNet PoseRanker (ANPR)' with improved performance.

biopharmatrend.com
Read News

Atomwise FAQ - Frequently Asked Questions About Founder, CEO, Funding & Company Details

Find answers to the most common questions about Atomwise including information about founders, CEO, funding history, investors, headquarters location, and company details. 19 frequently asked questions covering key information about the company.

Atomwise Questions & Answers - Company Information

Q1

What is Atomwise?

Atomwise is a preclinical pharma company revolutionizing drug discovery with AI technology. The company focuses on developing its own pipeline while nurturing numerous collaborations with researchers and pharmaceutical firms worldwide.

Q2

Who founded Atomwise?

Atomwise was founded by Abraham Heifets, Izhar Wallach.

Q3

Who is the CEO of Atomwise?

The CEO of Atomwise is Steve Worland. You can find more information about them on their LinkedIn profile.

Q4

How much funding has Atomwise raised?

Atomwise has raised a total of $$175 Million across 10 funding rounds. The most recent funding was completed on 2024-02-01.

Q5

Who are the investors in Atomwise?

Atomwise's key investors include Bill & Melinda Gates Foundation, B Capital Group, Sanabil Investments.

Q6

Where is Atomwise headquartered?

Atomwise is headquartered in San Francisco, California, United States.

Q7

When was Atomwise founded?

Atomwise was founded in 2012.

Q8

How many employees does Atomwise have?

Atomwise has 31-50 employees.

Q9

What is Atomwise's official website?

You can visit Atomwise's official website at http://www.atomwise.com.

Q10

What was Atomwise's latest funding round?

Atomwise's latest funding round was a Series C round of $$45 Million completed on 2024-02-01.

Q11

Who is founder?

Steve Worland

Q12

Who is cto?

Izhar Wallach

Q13

What does the company do?

Atomwise specializes in using artificial intelligence for drug discovery, particularly in preclinical drug development.

Q14

How much funding?

$175 Million

Q15

Latest funding date?

2024-02-01

Q16

Who are the investors?

Bill & Melinda Gates Foundation B Capital Group Sanabil Investments

Q17

What are the challenges?

Competition in AI drug discovery Regulatory hurdles

Q18

What are the opportunities?

Expanding partnerships Innovating in drug discovery technologies

Q19

Latest news?

Atomwise appoints Steve Worland, Ph.D. as Chief Executive Officer. Atomwise recently introduced A.I. based 'AtomNet PoseRanker (ANPR)' with improved performance.

More Information About Atomwise

For additional details about Atomwise, including the latest news, funding updates, and company developments, explore our comprehensive company database. Find information about startup funding, company valuations, executive leadership, and business intelligence data.